Chris Jacobs bought Akero Therapeutics Inc (NASDAQ: AKRO)
Chris Jacobs (R-NY), a U.S. Representative, has disclosed 1 trade in Akero Therapeutics Inc (AKRO) since 2022, a single purchase, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a purchase: Chris Jacobs bought $1,001 - $15,000 of Akero Therapeutics Inc (NASDAQ: AKRO) on November 8, 2022. Since that trade, AKRO is up +0.00% against the S&P 500 up +100.11%, an outperformance of -100.11%.
Data updated
Chris Jacobs's AKRO trades vs the price
AKRO is up +0.00% since Chris Jacobs bought on November 8, 2022, versus +100.11% for the S&P 500.
Performance since this trade
All Chris Jacobs AKRO trades
Chris Jacobs & AKRO trading FAQ
Is it legal for Chris Jacobs to trade Akero Therapeutics Inc (AKRO) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Akero Therapeutics Inc (AKRO), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Chris Jacobs buy AKRO?
Chris Jacobs disclosed a purchase of $1,001 - $15,000 of Akero Therapeutics Inc (AKRO) on November 8, 2022, according to public STOCK Act filings.
How has AKRO performed since Chris Jacobs's trade?
Since Chris Jacobs bought AKRO on November 8, 2022, the stock is up +0.00%, versus +100.11% for the S&P 500 over the same period, an outperformance of -100.11%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional AKRO trades?
Quantellect tracks every disclosed congressional trade in Akero Therapeutics Inc (AKRO) on the Akero Therapeutics Inc congressional trading page, which aggregates filings across all members of Congress.
Chris Jacobs's AKRO tradesAll congressional filings for Akero Therapeutics IncChris Jacobs's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.